• Seon Ha Baek, Kook-Hwan Oh, Sejoong Kim, Dong Ki Kim, Kwon-Wook Joo, Yun Kyu Oh, Byoung Geun Han, Jae Hyun Chang, Wookyung Chung, Yon Su Kim, and Ki Young Na.
• Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam 463-707, Gyeonggi-do, South Korea. kyna@snubh.org.
• Trials. 2014 Jan 1;15:432.

BackgroundThe clinical benefits of bioimpedance spectroscopy (BIS)-guided fluid management in patients on hemodialysis have been widely demonstrated. However, no previous reports have evaluated the effect of regular and serial BIS-guided fluid management on the residual renal function (RRF) in patients on peritoneal dialysis (PD). Therefore, we will evaluate the clinical efficacy of BIS-guided fluid management for preserving RRF and protecting cardiovascular events in patients on PD.Methods/DesignThis is a multicenter, prospective, randomized controlled trial. A total of 138 participants on PD will be enrolled and randomly assigned to receive either BIS-guided fluid management or fluid management based only on the clinical information for 1 year. The primary outcome is the change in the glomerular filtration rate (GFR) between months 0 and 12 after starting treatment. The secondary outcomes will include GFR at month 12, time to the anuric state (urine volume <100 ml/day), and fatal and nonfatal cardiovascular events during treatment.DiscussionThis is the first clinical trial to investigate the effect of BIS-guided fluid management on RRF and for protecting against cardiovascular events in patients on PD.Trial RegistrationClinical Trials.gov number NCT01887262, June 24, 2013.

34 keywords...

hide…